Nivolumab plus ipilimumab vs chemotherapy as first-line treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma: CheckMate 649 biomarker analyses

被引：2
|
作者：
Janjigian, Yelena Y.
Shitara, Kohei
Ajani, Jaffer
Moehler, Markus
Yao, Jin
Shen, Lin
Garrido, Marcelo
Gallardo, Carlos
Wyrwicz, Lucjan
Yamaguchi, Kensei
Skoczylas, Tomasz
Bragagnoli, Arinilda
Liu, Tianshu
Schenker, Michael
Yanez, Patricio
Kowalyszyn, Ruben
Karamouzis, Michalis
Zander, Thomas
Feeney, Kynan
Elimova, Elena
Nathani, Raheel
Novosiadly, Ruslan
Lei, Ming
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2023-CT037
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT037
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/ gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): Additional analyses from 4year (y) follow-up (FU) of CheckMate 649
    Wyrwicz, L. S.
    Shitara, K.
    Moehler, M.
    Ajani, J. A.
    Shen, L.
    Garrido, M.
    Gallardo Araneda, C. E.
    Yamaguchi, K.
    Cleary, J.
    Elimova, E.
    Bruges Maya, R.
    Karamouzis, M. V.
    Skoczylas, T.
    Bragagnoli, A. C.
    Liu, T.
    Tehfe, M.
    Feeney, K.
    Wang, R.
    Zhang, J.
    Janjigian, Y. Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S169 - S170
  • [22] Nivolumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: a cost-effectiveness analysis
    Peng-Fei Zhang
    Xuan-Qiong Shi
    Qiu Li
    Cost Effectiveness and Resource Allocation, 21
  • [23] Nivolumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: a cost-effectiveness analysis
    Zhang, Peng-Fei
    Shi, Xuan-Qiong
    Li, Qiu
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2023, 21 (01)
  • [24] First-Line (1L) nivolumab (NIVO) plus chemotherapy (chemo) versus chemo in patients (pts) with advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese subgroup analysis.
    Shen, Lin
    Bai, Yuxian
    Lin, Xiaoyan
    Li, Wei
    Wang, Jufeng
    Zhang, Xiaochun
    Pan, Hongming
    Bai, Chunmei
    Bai, Li
    Cheng, Ying
    Zhang, Jingdong
    Zhong, Haijun
    Ba, Yi
    Hu, Wenwei
    Xu, Ruihua
    Guo, Weijian
    Qin, Shukui
    Yang, Nong
    Lu, Jianwei
    Shitara, Kohei
    Lei, Ming
    Li, Mingshun
    Bao, Nicole
    Chen, Tian
    Liu, Tianshu
    CANCER RESEARCH, 2021, 81 (13)
  • [25] First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) versus chemo in advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): Expanded efficacy and safety data from CheckMate 649.
    Moehler, Markus H.
    Shitara, Kohei
    Garrido, Marcelo
    Salman, Pamela
    Shen, Lin
    Wyrwicz, Lucjan
    Yamaguchi, Kensei
    Skoczylas, Tomasz
    Bragagnoli, Arinilda Silva Campos
    Liu, Tianshu
    Schenker, Michael
    Yanez, Patricio Eduardo
    Tehfe, Mustapha
    Li, Mingshun
    Cullen, Dana
    Memaj, Arteid
    Lei, Ming
    Xiao, Hong
    Janjigian, Yelena Y.
    Ajani, Jaffer A.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [26] Tislelizumab Plus Chemotherapy as First-line Treatment for Advanced Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma
    Xu, Jianming
    Bai, Yuxian
    Xu, Nong
    Li, Enxiao
    Wang, Buhai
    Wang, Jin
    Li, Xiang
    Wang, Xin
    Yuan, Xianglin
    CLINICAL CANCER RESEARCH, 2020, 26 (17) : 4542 - 4550
  • [27] Cost-utility of sintilimab plus chemotherapy vs chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction cancer in China
    Li, Wei
    Wan, Li
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2024, 24 (05) : 671 - 678
  • [28] POPULATION PHARMACOKINETIC (PPK) AND EXPOSURE-RESPONSE EVALUATION OF NIVOLUMAB WITH CHEMOTHERAPY AS FIRST LINE TREATMENT IN PATIENTS WITH GASTRIC/GASTROESOPHAGEAL JUNCTION/ESOPHAGEAL ADENOCARCINOMA (CHECKMATE-649:CM649).
    Yang, H.
    Li, L.
    Ludwig, E.
    Passarell, J.
    Barcomb, H.
    Jaworowicz, D.
    Poulart, V.
    Li, M.
    Gao, L.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 : S58 - S58
  • [29] First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese subgroup analysis with 3-year follow-up.
    Shen, Lin
    Bai, Yuxian
    Lin, Xiaoyan
    Li, Wei
    Wang, Jufeng
    Zhang, Xiaochun
    Pan, Hongming
    Bai, Chunmei
    Bai, Li
    Cheng, Ying
    Zhang, Jingdong
    Zhong, Haijun
    Ba, Yi
    Hu, Wenwei
    Xu, Rui-Hua
    Guo, Weijian
    Qin, Shukui
    Wang, Rui
    Sullivan, Kendall
    Liu, Tianshu
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 353 - 353
  • [30] First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese subgroup analysis 4-year (yr) follow-up
    Shen, Lin
    Bai, Yuxian
    Lin, Xiaoyan
    Li, Wei
    Wang, Jufeng
    Zhang, Xiaochun
    Pan, Hongming
    Bai, Chunmei
    Bai, Li
    Cheng, Ying
    Zhang, Jingdong
    Zhong, Haijun
    Ba, Yi
    Hu, Wenwei
    Xu, Rui-Hua
    Guo, Weijian
    Qin, Shukui
    Wang, Rui
    McCraith, Stephen
    Liu, Tianshu
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 318 - 318
12345